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The primary aim of the trial was to investigate the influence of menopause on the incorporation of marine n-3 PUFA into platelets and adipose
tissue. A secondary aim was to evaluate whether marine n-3 PUFA may change levels of circulating oestrogens in women. Ninety-two pre- and
postmenopausal women were randomly assigned to consume 2·2 g of marine n-3 PUFA or control oil daily for 12 weeks. Adipose tissue biopsies
and blood samples were collected at baseline and after intervention. Eighty-nine women completed the study. Baseline contents of total marine
n-3 PUFA and each of the major long-chained n-3 PUFA, EPA, docosapentaenoic acid and DHA were all significantly lower (P,0·05) in the
premenopausal group both in platelets and adipose tissue, except for EPA in platelets (P¼0·05). After supplementation with fish oil, the content
of all marine n-3 PUFA increased significantly in platelets and adipose tissue in both pre- and postmenopausal women. The increase in platelets
and adipose tissue was, however, the same in both groups. There was no effect of fish oil on oestrogen levels in postmenopausal women. We found
a significant difference in premenopausal women, in whom oestradiol (P,0·04) and oestrone (P,0·02) serum concentrations increased after the
fish oil supplement. This trial did not reveal any difference in the ability of pre- and postmenopausal women to incorporate marine n-3 PUFA into
platelets or adipose tissue. However, supplementation with fish oil increased oestrogen levels in premenopausal women.
Randomised clinical trials: n-3 Fatty acids: Oestrogens: Adipose tissue: Menopause: Platelets
CVD and breast cancer (BC) have a major impact on morbid-
ity and mortality among women in the Western world(1 – 3).
It is therefore important to identify modifiable risk factors
that may prevent these diseases and improve their prognoses.
A high intake of marine n-3 PUFA from fish is associated with
a reduced risk of CVD(4) and possibly also of several cancer
forms including BC(5,6). Some of the proposed mechanisms
behind the protective effect of marine n-3 PUFA are similar
in both diseases, including production of eicosanoids with
a more anti-inflammatory profile and effects on the properties
of the cell membrane(7). Most clinical studies in CVD
have been dominated by male participants, and the results
and recommendations have been extrapolated to women,
although coronary disease may be of a different character in
women(8). The risk of CVD in women increases dramatically
with menopause, probably due to a significant reduction in
the synthesis of oestrogens(9). The incidence of BC also
increases rapidly with age, but the increase slows down at
menopause, indicating the importance of female hormones
for the development of BC(2).
The influence of menopause on the uptake and on the
subsequent turnover of marine n-3 PUFA in the body is
largely unknown. Several studies have shown that DHA
concentrations in different tissues are higher in women
than in men, independent of diet(10 – 13), and that treatment
with oral contraceptives or oestrogens affects levels of
DHA(14 – 18). Stable isotope studies have also shown that
women have a much greater capacity to convert a-linolenic
acid to DHA compared to men of similar age(19,20). All
these studies indicate that the content of marine n-3 PUFA
in tissues is, to some extent, under the influence of oestrogen
levels in the body.
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Furthermore, marine n-3 PUFA may reduce the activity of
aromatase enzymes which convert androgens to oestrogen, thus
leading to a potential oestrogen-lowering effect in the body(6).
To study whether the incorporation of marine n-3 PUFA
into cells (platelets) and adipose tissue was influenced by
menopausal status, and whether the levels of oestrogens in
the blood were influenced by supplementation with marine
n-3 PUFA, we performed a randomised, parallel-group,
double-blind, placebo-controlled trial.
Material and methods
Study population
During 2007, ninety-two Danish women were recruited
primarily among employees at Aalborg Hospital and among
women living in Northern Jutland in Denmark. Eligible women
were aged between 18 and 70 years, healthy or with a chronic,
stable and well-treated disease (i.e. hypertension, diabetes
mellitus), and a menopausal status that was unambiguous.
The menopausal status was defined as a spontaneous cessation
of menses for 12 months or longer, and, in case of doubt,
we also measured follicle-stimulating hormone and luteinising
hormone. Hysterectomised women could be included if
they were aged 60 years or older, or their follicle-stimulating
hormone and luteinising hormone values were clearly post-
menopausal. Criteria for exclusion were consumption of fish oil
products, any form of hormones including oral contraceptives
during the last 2 months before enrolment, known allergies
to fish and anticipated compliance problems. Vaginal local
oestrogen therapy was accepted. Half of the women were
premenopausal and the rest postmenopausal.
The present study was conducted according to the guide-
lines laid down in the Declaration of Helsinki.
All participants gave written informed consent before parti-
cipating in the trial. The study protocol was approved by the
ethics committee of the Region of Northern Jutland and by
the Danish Data Protection Agency. If any abnormal labora-
tory value was found, the participants were referred to their
general practitioner for further investigation. The study was
registered in ClinicalTrials.gov (identifier: NCT00901589).
Intervention
The participants were randomly assigned to receive 12 weeks’
daily supplementation with either 2·2 g n-3 PUFA (38·5 %
EPA, 25·9 % DHA and 6·0 % docosapentaenoic acid (DPA))
in four capsules, or four corresponding capsules of a control
oil (thistle oil) containing 73·7 % linoleic (18 : 2n-6), 11·7 %
oleic (18 : 1n-9), 6·8 % palmitic (16 : 0) and 2·4 % stearic
(18 : 0) acids. The two types of capsules were identically
coloured gelatine capsules provided and packed by Mezina
A/S, Esbjerg, Denmark. Thistle oil was chosen due to a very
limited content of n-3 PUFA, neutral taste and availability.
Study design
The study was designed as a randomised, double-blind,
placebo-controlled, parallel-group intervention trial. The ran-
domisation process was computer-generated and conducted
by an independent statistician at the Center for Cardiovascular
Research at Aalborg Hospital. Participants, investigators and
laboratory staff were blinded to dietary assignments during
the entire study. Blood samples and adipose tissue biopsies
were collected at baseline and after 12 weeks of intervention,
in the morning after a minimum of 8 h fasting. Hormones
fluctuate during the menstrual cycle and in order to reduce
the effect of this natural fluctuation, the blood samples in the
premenopausal group were taken early during the week the
participants menstruated. Anthropometric measurements
(weight, height, blood pressure and bioimpedance) were
obtained before and after the interventions. Before and after
the intervention period, the participants filled in a question-
naire that assessed their health status, intake of medicine,
diet, exercise level and alcohol consumption.
Participants were requested to follow their usual diet
throughout the study period. Compliance was examined by
counting the remaining capsules and by fatty acid analyses.
Fatty acid analysis
Adipose tissue. Adipose tissue biopsies were obtained
from the buttocks using an evacuated system consisting of
S-Monovette needle, multiadaptor and evacuated blood tube
(Sarstedt, D-51 588 Nu¨mbrecht, Germany), as described by
Beynen & Katan(21). The fat was stored in vials filled with
nitrogen at 2808C to avoid oxidation until analysis, which
was performed at the end of the study period. The biopsies
were defrosted at room temperature, and a sample of approxi-
mately 2–4 mg was removed to a test-tube, and pre-warmed
to 508C for 10 min. The fat was dissolved in heptane at
508C and the fatty acids were trans-esterified by 2 M KOH
in methanol at 508C for 2 min, according to IUPAC 2.301,
chapter 5(22). The fatty acid composition was analysed by
GC using a Varian 3900 GC with a CP-8400 autosampler
(Varian, Middleburg, The Netherlands) equipped with a
flame ionisation detector. Split injection mode, a CP-sil 88,
60 m £ 0·25 mm inner diameter capillary column (Varian,
Middleburg, The Netherlands), temperature programming
from 90 to 2108C and constant flow were used. Helium was
used as a carrier gas. Commercially available standards
(Nu-chek-Prep, Inc., MN, USA) were used to recognise the
individual fatty acids.
These approaches permitted quantification of fatty acid
methyl esters with 12–24 carbon atoms and separation and
quantisation of several trans fatty acids. The fatty acid content
is presented as the percentage of total fatty acids. The inter-
assay CV, calculated from repeated analyses of samples on
different days, was 6·3 % for EPA, 4·3 % for DPA and 5·2 %
for DHA.
Platelets. Platelets were separated from blood and anti-
coagulated with 1·6 mg/ml of K-EDTA. The tubes were left
at ambient temperature for half an hour for sedimentation
before centrifugation for 15 min at 180 g. Platelet-rich plasma
was harvested and centrifuged for 5 min at 150 g to remove
remaining leucocytes and erythrocytes. The platelet-rich
plasma was transferred to a new plastic tube and centrifuged
for 10 min at 1500 g to sediment the platelets. The platelet poor
plasma was discharged, the cells were resuspended and
washed twice in isotonic saline, centrifuged each time for
10 min at 1500 g. The precipitate was resuspended in
isotonic saline and stored in the same way as adipose tissue
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until analysis. Fatty acids were extracted from platelets
according to the method of van Kuijk et al. (23). Briefly, the
cell suspension was mixed with 1·0 ml dichloromethane and
1·0 ml methanol containing butylated hydroxytoluene 10 mg/
100 ml; another 1·0 ml of dichloromethane and 500ml H2O
were added, mixed and centrifuged for 4 min at 1800 g. The
lower organic phase was collected, and the extraction of the
supernatant was repeated. The combined lipid phase was
dried under nitrogen at 258C.
The fatty acid composition was analysed in the same way as
was used for adipose tissue. A similar platelet control sample
analysed in different runs showed the following interassay
CV: 0·9 % for EPA, 1·8 % for DPA and 2·6 % for DHA.
Analyses of oestrogens
Serum samples collected for hormonal analyses were frozen at
2208C and after completion of the study, analysed at the
Danish Serum Institute in Copenhagen, Denmark.
Quantification of oestrone, oestradiol and oestrone sulphate
levels. Oestrone (E1), oestradiol (E2) and oestrone sulphate
were measured using an in-house assay RIA. In brief, an
internal standard was added to serum aliquots before extrac-
tion and fractionation on C2 solid phase extraction cartridges
(Varian, Palo Alto, CA, USA). Oestrone sulphate was solvo-
lysed and converted to E1 before RIA analysis, which was
performed using in-house antibodies specific for either E1 or
E2 17-b. The functional limits of detection were 40, 40
and 200 pM for E1, E2 and oestrone sulphate, respectively.
The interassay CV were 14–18 % (E1), 12–16 % (E2) and
12–15 % (oestrone sulphate).
Quantification of non-sex hormone-binding globulin-bound
oestradiol level. Non-sex hormone-binding globulin
(SHBG)-bound E2 was measured as the percentage of total
E2 levels by equilibrating serum samples with 3H-E2, precipi-
tating the SHBG-bound 3H-E2 fraction with saturated
ammonium sulphate and estimating the radioactivity in the
supernatant by liquid scintillation counting (Beckman Coulter,
Fullerton, CA, USA). In order to account for possible precipi-
tation of albumin-bound 3H-E2, a separate set of sample
aliquots was incubated with 5a-dihydrotestosterone to saturate
SHBG-binding sites before ammonium sulphate precipitation.
The percentage of non-SHBG-bound E2 was calculated as the
sum of the percentage of radioactivity in the supernatant of
non-5a-dihydrotestosterone-treated samples and the percen-
tage of radioactivity in the precipitate of 5a-dihydrotestoster-
one-treated samples. The interassay CV was 5–14 %.
Additional analyses
Basic safety parameters and standard lipid analyses were per-
formed according to the standard methods at the Department
of Clinical Biochemistry at Aalborg Hospital.
Measurement of apo B was done on an Advia 1650
(Siemens Healthcare Diagnostics, Deerfield, IL, USA) at the
Department of Clinical Biochemistry in Hjørring, Denmark.
Statistical analyses
The number of women needed for the trial was calculated
from data on changes in the content of marine n-3 PUFA
after supplementation with fish oil in women in a previous
study(24). The SD was estimated to be 0·3 %, and in order
not to miss a true difference of 0·25 % between the two
groups after supplementation with marine n-3 PUFA, we
included twenty-two women in each group. The risk of type
1 error was set at 5 % and the risk of type 2 error was set
at 20 %.
Comparison of baseline characteristics in the different
groups was performed using a paired t test for continuous
variables and a x 2 test for frequencies. Mann–Whitney
two-sample rank-sum test was used for parameters with a
non-normal distribution.
The change in marine n-3 PUFA from baseline to 12 weeks
after intervention on the subject level was analysed by a
two-way ANOVA, the factors being menopausal state and
treatment group. Hence, a possible difference in treatment
effect between menopausal groups could be assessed by
analysing the statistical interaction between the factors.
Furthermore, the treatment effect and the difference between
menopausal groups can also be assessed. Adjustment for
age was done by including age in a two-way analysis of
co-variance. A P value below 0·05 was regarded as significant.
All analyses were performed with Stata version 10.1
(Stata Corporation, College Station, TX, USA).
Results
A total of eighty-nine women completed the study. One
woman was excluded due to pathological baseline laboratory
parameters and two withdrew their consent. The compliance
to the intervention was high, with few reported side effects,
primarily gastrointestinal (fishy taste and eructation). There
was no apparent change in dietary habits in any of the
groups as judged from the questionnaires filled in before and
after the intervention (data not shown).
The women were well-matched for baseline characteristics
in both the pre- and the postmenopausal groups, respectively.
Blood pressure, glucose, total cholesterol, HDL and LDL
cholesterol, and apo B levels were significantly higher in
postmenopausal women (Table 1).
At baseline, a significantly higher content of all marine n-3
PUFA was found in platelets (P,0·05) and adipose tissue
(P,0·001) in the postmenopausal women compared with the
premenopausal, except for the content of EPA in platelets
(P¼0·05; Tables 2 and 3).
Fatty acid results
Tables 2 and 3 show the differences in fatty acid composition
in platelets and in adipose tissue before and after 12 weeks of
intervention. The control oil had no effect on the content of
marine n-3 PUFA in the pre- or postmenopausal women. In
the fish oil groups, there were significant increases in total
marine n-3 PUFA, EPA, DPA and DHA in both groups, in
platelets as well as in adipose tissue. The increase in marine
n-3 PUFA was larger in platelets than in adipose tissue, and
in both compartments the largest relative increase was seen
in EPA content. Significant changes in the content in platelets
of several fatty acids including arachidonic acid were
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observed in both pre- and postmenopausal women treated with
fish oil.
We found no effect of menopausal status on the increase of
marine n-3 PUFA, either in platelets or in adipose tissue,
(Table 4), and there was no effect of age on the increase.
Hormone analyses
Table 5 shows that all levels of oestrogens were significantly
lower in postmenopausal than in premenopausal women.
In postmenopausal women, fish oil and control oil had no
detectable effect on oestrogen levels. However, levels of
both E2 (P,0·04) and E1 (P,0·02) increased significantly
in premenopausal women in the fish oil group compared
with the control group.
Discussion
The present study aimed to evaluate whether menopause
affected the incorporation of marine n-3 PUFA into platelets
and adipose tissue. We also examined whether supplemen-
tation with marine n-3 PUFA had any effect on the concen-
tration of circulating oestrogens in women.
This trial of 12 weeks of supplementation with marine n-3
PUFA demonstrated that pre- and postmenopausal women are
equally efficient at incorporating marine n-3 PUFA into plate-
lets and adipose tissue. We found significantly higher baseline
levels of marine n-3 PUFA in platelets and adipose tissue in
postmenopausal women compared with premenopausal
women, which is in accordance with some other studies(25,26).
In contrast to the present study, a previous intervention
study showed that 3 months of fish oil supplementation
(2·4 g of EPA þ DHA/d) resulted in a significantly higher
increase of DHA and EPA in plasma fatty acids in older
women than in younger women(27). However, the study was
small (n 25) and did not include a placebo group or control
for diet during the intervention period. In a placebo-controlled
intervention study with EPA (supplementation with 1·35, 2·7,
or 4·05 g/d) to ninety-three men, there was a significantly
larger incorporation of EPA into plasma and mononuclear
cell phospholipids in older men compared with younger
men, consistent with higher baseline EPA content in the
older men(28). A limitation to that study was that there was
no record of dietary habits.
Other studies indicate that fish intake may be higher in older
people than in younger(11,29), but even after adjusting for
this difference, older people seem to have a higher content
of marine n-3 PUFA in adipose tissue(29). The explanation
for the age-related effect is unknown, but one plausible
explanation might be a change of body composition with
age, and a decrease in energy expenditure, resulting in a
lower proportion of supplemented marine n-3 PUFA being
oxidised, and a higher proportion being incorporated into
tissues(28). Another plausible explanation might be reductions
in desaturase activity by age(30).
In addition to the age-related effect, several studies indicate
that hormones have an influence on the content of marine n-3
PUFA in the body(14). DHA concentrations are higher in
women than in men in several tissues, independent of
diet(10 – 13), and treatment with oral contraceptives or oestrogens
may affect levels of DHA(14 – 18). The difference in DHA con-
centrations between women and men is probably related to a
higher conversion of a-linolenic acid to EPA and DHA in
women, as shown in stable isotope studies. These studies also
indicates the regulatory effects of oestrogens(31). Treatment
with anastrozole (an aromatase inhibitor), on the other hand,
results in lower E2 and lower DHA in plasma(12). However,
the present study showed that the incorporation of marine n-3
PUFA from a dietary supplement into platelets and adipose
tissue was independent of menopausal status, and therefore
possibly independent of oestrogen concentrations.
Marine n-3 PUFA have an inhibitory effect on cyclo-oxyge-
nase-2 and might act as a potential aromatase P450 inhibitor,
resulting in a lower production of endogenous oestrogens(32).
Table 1. Baseline characteristics of participants*
(Mean values with their standard errors†)
Premenopausal Postmenopausal
Fish oil (n 23) Control (n 22) Fish oil (n 22) Control (n 23)
Mean SEM Mean SEM Mean SEM Mean SEM Pre v. post P
Age (years) 41·6 1·3 44·0 1·6 56·0 0·9 55·9 1·2 ,0·001
BMI (kg/m2) 24·5 21·8–29·3 24·6 21·6–27·0 24·5 21·9–26·9 23·1 22·1–27·4 0·9
Waist circumference (cm) 87·5 2·5 84·5 1·9 86·9 2·0 86·0 2·7 0·9
Fat tissue (%) 33·2 1·6 31·7 1·4 33·7 1·4 34·7 1·5 0·2
Blood pressure (mmHg)
Systolic 118 2 122 3 133 3 133 3 ,0·001
Diastolic 73 2 76 2 81 2 81 2 ,0·01
Plasma biochemistry
Glucose (mM) 5·1 0·1 5·0 0·1 5·3 0·1 5·4 0·1 ,0·01
TC (mM) 4·2 0·1 4·6 0·2 5·4 0·2 5·3 0·2 ,0·001
LDL (mM) 2·3 0·1 2·7 0·2 3·0 0·1 3·0 0·2 ,0·001
HDL (mM) 1·6 0·1 1·6 0·1 2·0 0·1 1·9 0·1 ,0·01
TAG (mM) 0·8 0·1 0·8 0·1 0·9 0·1 1·1 0·1 0·1
Apo B (g/l) 0·87 0·10 0·98 0·06 1·10 0·04 1·13 0·4 ,0·001
Pre, premenopausal; post, postmenopausal; TC, total cholesterol; LDL, LDL cholesterol; HDL, HDL cholesterol.
* Comparison between fish oil and control groups in pre- and postmenopausal women, respectively, and comparison between pre- and postmenopausal women.
† BMI is presented as medians and quartile ranges.
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Table 2. Platelet fatty acid composition of the four arms*
(Mean values and standard deviations or median values and quartile ranges)
Premenopausal fish oil (n 23) Premenopausal control (n 22) Postmenopausal fish oil (n 22) Postmenopausal control (n 22)
Baseline 12 weeks Baseline 12 weeks Baseline 12 weeks Baseline 12 weeks
Mean SD Mean SD Mean SD Mean SD P † Mean SD Mean SD Mean SD Mean SD P †
Palmitic acid (16 : 0) 16·3 1·0 16·6 1·1 16·3 0·9 16·2 1·1 ,0·05 16·2 1·0 16·5 0·9 16·2 1·0 16·2 0·9 0·05
Stearic acid (18 : 0) 19·7 1·0 19·5 1·1 19·2 0·7 19·4 0·9 ,0·05 19·4 0·8 19·1 0·8 19·5 1·0 19·6 1·0 ,0·01
Oleic acid (18 : 1n-9) 16·8 0·6 17·7 0·8 16·9 0·8 16·8 1·0 ,0·01 16·6 1·0 17·9 0·8 16·6 0·8 16·4 0·7 ,0·01
Linoleic acid (18 : 2n-6) 5·3 0·6 5·1 0·5 5·1 0·6 5·5 0·5 ,0·01 4·8 0·4 4·7 0·4 5·1 0·6 5·6 0·6 ,0·01
a-Linolenic acid (18 : 3n-3) 0·2 0·4 0·2 0·0 0·2 0·1 0·2 0·1 0·33 0·2 0·0 0·2 0·0 0·2 0·0 0·2 0·0 0·8
Arachidonic acid (20 :4n-6) 26·0 0·8 22·8 1·8 25·7 1·0 25·5 1·4 ,0·01 26·2 1·4 22·6 1·5 25·7 1·1 25·4 1·4 ,0·01
EPA (20 : 5n-3) 0·6 0·5–0·8 2·6 1·9–4·0 0·8 0·6–1·0 0·8 0·6–1·0 ,0·01 0·8 0·6–1·1 3·0 2·6–3·7 1·0 0·7–1·3 0·8 0·8–1·3 ,0·01
DPA (22 : 5n-3) 1·7 1·6–1·8 2·6 2·3–2·8 1·7 1·6–1·8 1·6 1·5–1·8 ,0·01 1·8 1·6–2·0 2·6 2·3–3·0 1·9 1·7–2·0 1·9 1·7–2·0 ,0·01
DHA (22 : 6n-3) 2·1 1·8–2·4 2·8 2·6–3·1 2·3 2·1–2·5 2·3 2·0–2·4 ,0·01 2·3 2·1–2·6 2·9 2·7–3·3 2·7 2·4–3·0 2·6 2·2–3·0 ,0·01
Total EPA þ DPA þ DHA 4·5 4·1–5·1 7·9 7·3–9·7 4·8 4·3–5·6 4·9 4·2–5·2 ,0·01 5·0 4·3–5·7 8·7 8·1–9·3 5·9 4·7–6·3 5·6 4·6–6·0 ,0·01
DPA, docosapentaenoic acid.
* Comparison between baseline and 12 weeks of intervention. The fatty acids are reported as % of total fatty acids.
† The difference in content before and after intervention is compared in pre- and postmenopausal women, respectively.
Table 3. Adipose tissue fatty acid composition of the four arms*
(Mean values and standard deviations or median values and quartile ranges)
Premenopausal fish oil (n 23) Premenopausal control (n 22) Postmenopausal fish oil (n 22) Postmenopausal control (n 22)
Baseline 12 weeks Baseline 12 weeks Baseline 12 weeks Baseline 12 weeks
Mean SD Mean SD Mean SD Mean SD P † Mean SD Mean SD Mean SD Mean SD P †
Palmitic acid (16 : 0) 19·4 2·2 19·4 2·1 18·8 1·7 18·8 1·8 0·9 18·7 1·6 18·6 1·9 18·7 1·8 18·5 1·9 0·6
Stearic acid (18 : 0) 2·7 0·7 2·7 0·7 2·6 0·6 2·6 0·6 0·5 2·5 0·7 2·5 0·7 2·5 0·6 2·4 0·5 0·6
Oleic acid (18 : 1n-9) 48·0 1·6 48·0 1·5 48·8 1·7 48·2 1·7 0·9 47·7 1·4 47·7 1·4 47·5 1·1 47·4 1·3 0·6
Linoleic acid (18 : 2n-6) 11·1 1·2 11·1 1·2 10·6 1·1 10·8 1·2 ,0·05 9·9 0·9 9·8 0·8 10·7 1·1 11·0 1·2 ,0·05
a-Linolenic acid (18 :3n-3) 0·8 0·1 0·8 0·2 0·7 0·1 0·8 0·1 0·9 0·7 0·1 0·7 0·1 0·8 0·1 0·8 0·1 0·6
Arachidonic acid (20 :4n-6) 0·4 0·1 0·4 0·1 0·4 0·1 0·4 0·1 0·4 0·5 0·1 0·5 0·1 0·4 0·1 0·4 0·1 0·9
EPA (20 : 5n-3) 0·1 0·0–0·1 0·1 0·1–0·2 0·1 0·1–0·1 0·1 0·1–0·1 ,0·01 0·1 0·1–0·2 0·2 0·2–0·2 0·1 0·1–0·2 0·1 0·1–0·2 ,0·01
DPA (22 : 5n-3) 0·2 0·2–0·3 0·3 0·2–0·3 0·2 0·2–0·3 0·2 0·2–0·3 ,0·01 0·3 0·3–0·4 0·4 0·3–0·4 0·3 0·3–0·4 0·3 0·3–0·4 ,0·01
DHA (22 : 6n-3) 0·2 0·1–0·3 0·2 0·2–0·3 0·2 0·2–0·3 0·3 0·2–0·3 ,0·01 0·3 0·2–0·4 0·4 0·3–0·4 0·3 0·2–0·4 0·3 0·2–0·4 ,0·01
Total EPA þ DPA þ DHA 0·5 0·4–0·6 0·6 0·6–0·9 0·6 0·4–0·7 0·6 0·4–0·8 ,0·01 0·7 0·5–0·9 0·9 0·8–1·0 0·7 0·5–0·9 0·7 0·6–0·9 ,0·01
DPA, docosapentaenoic acid.
* Comparison between baseline and 12 weeks of intervention. The fatty acids are reported as % of total fatty acids.
† The difference before and after intervention is compared in pre- and postmenopausal women, respectively.
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In addition, the production of PGE3, an eicosanoid product
from the metabolism of EPA, has a less activating effect on
the aromatase enzyme than the arachidonic acid-derived
PGE2, and hence may result in a decrease in oestrogen con-
centrations(6). The present study, however, could not support
these mechanisms. In fact, contrary to our expectation, we
found a significant increase in E2 and E1 in premenopausal
women supplemented with fish oil and no effect in postmeno-
pausal women. The mechanisms behind this are unknown and
whether there is an absolute increase, an increase in
bioavailable oestrogens or a decrease in the metabolism of
oestrogens, or all three, remain to be settled. We analysed
non-SHBG-bound E2 because there may be a good correlation
between non-SHBG E2 and BC risk(33) and because the
analysis is more readily available than the measurement of
free E2. Supplementation with fish oil had, however, no
effect on this parameter. Supplementary analyses of free E2
and SHBG might have provided more information.
There was a significant decrease in the content of arachido-
nic acid in platelets in both pre- and postmenopausal women
given fish oil, suggesting a reduced formation of proaggrega-
tory thromboxane A2 after stimulation which may partially
explain the beneficial effect of marine n-3 PUFA in CVD(34).
The strengths of the present study were the study design and
a reliable confirmation of the high compliance of participants
and the measurements of marine n-3 fatty acids in both
platelets and adipose tissue. There were few withdrawals,
and the use of a questionnaire also helped to evaluate potential
changes in dietary habits during the intervention period.
The limitations were that the intervention period of 12
weeks may have been too short to detect a difference in the
fatty acid content in adipose tissue in the two groups(35).
The composition of fatty acids in platelets and adipose
tissue reflects the dietary intake of PUFA, the former over
weeks and the latter over months/years(35 – 37). Also, our ques-
tionnaire was not designed to evaluate the absolute amounts of
Table 4. The mean increase in marine n-3 PUFA in platelets and in adipose tissue after 12 weeks of intervention with fish oil*
(Mean values and standard deviations)
Platelets Adipose tissue
Premenopausal
(n 23)
Postmenopausal
(n 22)
Premenopausal
(n 23)
Postmenopausal
(n 22)
Mean SD Mean SD Mean SD Mean SD
EPA (20 : 5n-3) 2·1 0·9 2·2 0·6 0·1 0·0 0·1 0·0
DPA (22 : 5n-3) 0·8 0·3 0·9 0·2 0·0 0·0 0·1 0·0
DHA (22 : 6n-3) 0·7 0·3 0·6 0·3 0·1 0·0 0·1 0·1
Total EPA þ DPA þ DHA 3·6 1·4 3·7 0·9 0·2 0·1 0·2 0·1
DPA, docosapentaenoic acid.
* The increase is reported as % of total fatty acids.
Table 5. Oestrogen concentrations before and after intervention in pre- and postnopausal women
(Median values and quartile ranges)
Premenopausal fish oil (n 23) Premenopausal control (n 22)
Baseline 12 weeks Baseline 12 weeks
Median
Quartiles
(Q1–Q3) Median
Quartiles
(Q1–Q3) Median
Quartiles
(Q1–Q3) Median
Quartiles
(Q1–Q3) P *
Oestradiol (pM) 160 110–220 210 110–280 200 180–370 220 120–250 0·02
Oestrone (pM) 160 110–260 170 130–280 195 140–300 160 100–200 0·04
NonSHBGp (%) 47 37–56 44 38–55 40 36–44 41 38–45 0·74
NonSHBGm (pM) 82 58–133 87·5 46–118 82 58–133 87·5 46–118 0·1
Oestrone sulphate (pM) 3500 2700–4400 3400 2500–5000 4650 3100–5500 4100 2300–5500 0·24
Postmenopausal fish oil (n 22) Postmenopausal control (n 22)
Baseline 12 weeks Baseline 12 weeks
Median
Quartiles
(Q1–Q3) Median
Quartiles
(Q1–Q3) Median
Quartiles
(Q1–Q3) Median
Quartiles
(Q1–Q3) P *
Oestradiol (pM) 61 10–130 55·5 10–130 105 10–160 115 10–170 0·1
Oestrone (pM) 83·5 40–150 91·5 43–120 120 10–180 110 10–130 0·37
NonSHBGp (%) 43·5 33–55 41·5 34–51 44 36–54 48 39–54 0·08
NonSHBGm (pM) 22·5 15–48 27·5 15–51 55·5 20–83 47 15–78 0·47
Oestrone sulphate (pM) 2050 1600–2400 2100 1900–2200 2250 2100–3300 2450 2100–4000 0·83
NonSHBG, non-sex hormone-binding globulin-bound oestradiol.
* The differences in oestrogen concentrations before and after the intervention are compared in the two groups of women.
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daily fish intake, and hence we could not adjust for the actual
amount of fish eaten. To our knowledge, the study is the first
to evaluate whether marine n-3 PUFA have an effect on circu-
lating oestrogens in the human blood. Unfortunately, some of
the hormone measurements in the postmenopausal group were
below detection limit for the method of analysis and absolute
values could not be obtained. The results must therefore
be interpreted with caution. Endogenous hormone levels
are known risk factors for BC, but standardised methods
for routine measurement need to be developed and evalu-
ated(38). The aromatase enzyme is particularly expressed in
breast adipose tissue and in breast tumour tissue, and a more
conclusive assay might have been to evaluate the aromatase
activity or measure oestrogen levels in breast adipose tissue
before and after fish oil supplementation.
In conclusion, this trial demonstrated that pre- and post-
menopausal women are equally efficient at incorporating marine
n-3 PUFA into platelets and adipose tissue. We also found that
marine n-3 PUFA may increase the levels of oestrogens in
premenopausal women, thereby potentially affecting BC and
CVD risk. Further studies should explore the association
between marine n-3 PUFA and female sex hormones and its
clinical relevance.
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